Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse

Prostate

Volumn 56, Issue 3, 2003, Pages 183-191

  González Barcena, David ^a,c   Schally, Andrew V ^b   Vadillo Buenfil, Manuel ^a   Cortez Morales, Adolfo ^a   Hernández, L Victor ^a   Cardenas Cornejo, Imelda ^a   Comaru Schally, Ana Maria ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b TULANE UNIVERSITY   (United States)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Androgen independent tumors; Growth factors; Remission

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; KETOCONAZOLE; PANCREAS ENZYME; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE; TRIPTORELIN; VAPREOTIDE;

ABDOMINAL DISEASE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HUMAN TISSUE; MALE; MORTALITY; OPEN STUDY; ORCHIECTOMY; PERFORMANCE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAIN; PROSTATIC NEOPLASMS; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 17044446475     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10232     Document Type: Article

References (47)

1. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate 2000;45:158-166.
2. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC Jr., Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine. 4th ed. Baltimore: Williams and Wilkins; 1997. p 1067-1086.
3. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;23:1-44.
4. Gonzalez-Barcena D, Perez-Sanchez P, Ureta-Sanchez S, Berea-Domínguez H, Graef-Sánchez A, Becerril-Morales M, Comaru-Schally AM, Schally AV. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate 1985;7:21-30.
5. González-Barcena D, Pérez-Sánchez P, Berea-Domínguez H, Graef-Sánchez A, Becerril-Morales M, Comaru-Schally AM, Schally AV. Persistent Blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. Prostate 1986;9:207-215.
6. González-Barcena D, Pérez-Sánchez P, Graef-Sánchez A, Gomez AM, Berea H, Comaru-Schally AM, Schally AV. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-released formulation in patients carcinoma. Prostate 1989;14:291-300.
7. Crawford ED. Hormonal therapy of prostatic carcinoma; Defining the challenge. Cancer 1990;66:1035-1038.
8. González-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes-García M, Cardenas-Cornejo I, Graef-Sánchez A, Comaru-Schally AM, Schally AV. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84-92.
9. González-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-García M, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Luteinizing hormone-releasing hormone antagonist Cterorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995;45:275-281.
10. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-706.
11. Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984;5:1-17.
12. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma Insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
13. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-6985.
14. Lamberts SWJ. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
15. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34-38.
16. Patel YC, Greenwood MT, Panetta R, Hukovic N, Grigorakis S, Roberto LA, Srikant CB. Molecular biology of somatostatin receptor subtypes. Metabolism 1996;45:31-38.
17. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995;57:1249-1265.
18. Schonbrunn A, Gu YZ, Dournard P, Beaudet A, Tannenbaum GS, Brown PJ. Somatostatin receptor subtypes: Specific expression and signaling properties. Metabolism 1996;45:8-11.
19. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-442.
20. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-152.
21. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C. Inhibition of cell proliferation by somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanism. Proc Natl Acad Sci U S A 1995;92:1580-1584.
22. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Schally AV, Vaysse N, Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91:2315-2319.
23. Nilsson S, Reubi JC, Kalkner KM, Laissue JA, Horisberger U, Olerud C, Westlin JE. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe 1]-Octreotide scintigraphy. Cancer Res 1995;55:5805-5810.
24. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995;80:2806-2814.
25. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and Ribonucleic Acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000;85:2564-2571.
26. Schally AV, Redding TW. Somatostatin analogs as adjuncts to agonist of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 1987;84:7275-7279.
27. Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R3327H rat prostate cancer model. Prostate 1992;20:297-310.
28. Brevini TA, Bianchi R, Motta M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: Possible mechanism of action. J Clin Endocrinol Metab 1993;77:626-631.
29. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LH3RH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-5736.
30. Gonzalez-Barcena D, Molina-Ayala MA, Cortez-Morales A, Vadillo-Buenfil I, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Response to administration of somatostatin analog RC-I 60 (Vapreotide) in patients with advanced prostatic cancer at the relapse time. 80th Annual Meeting of the Endocrine Society, New Orleans, Louisiana. 1998 June 24-27. Abstract P3-164, p 421.
31. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
32. Hofland LJ, Van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SWJ. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 1994;134:301-306.
33. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996;56:1823-1827.
34. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14.
35. Nagy A, Schally AV. Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers. Drugs of the Future 2001;26:261-270.
36. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear Medicine Annual. New York: Raven Press; 1995. p 1-50.
37. Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, van Eijck CH. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001;88:31-40.
38. Thakur ML, Kolan H, Li J, Wiaderkiewicz R, Pallela VR, Duggaraju R, Schally AV. Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol 1997;24:105-113.
39. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analog of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 1998;58:4132-4137.
40. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999;59:1947-1953.
41. di Sant' Agnese PA. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;75:1850-1859.
42. Bosman FT. Neuroendocrine cells in non-endocrine tumors: What does it mean? Verh Dtsch Ges Pathol 1997;81:62-72.
43. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8.
44. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.
45. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
46. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
47. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer. Clin Cancer Res 2001;7:2854-2861.